Tick control debate sharpens around speed, duration, and retail tools
A Fear Free article published in February 2025 is resurfacing a clinically familiar but commercially important question in parasite prevention: when it comes to tick products, how much should veterinarians weigh speed of kill versus duration of protection? The article, “Tick-Tock: Comparing Speed and Duration of Tick Treatments,” highlights a head-to-head study in dogs that found lotilaner outperformed afoxolaner and sarolaner-based comparators against lone star ticks on both initial and residual speed of kill. At the same time, the consumer retail market is expanding around complementary tick tools, with TiCK MiTT announcing on March 31, 2026, that it will enter more than 900 Petco stores nationwide this spring. (fearfree.com)
The backdrop is a steady rise in concern over tick-borne disease risk for both pets and people. Fear Free frames the issue around preserving the human-animal bond through easier, more effective parasite prevention, and it emphasizes that some pathogens may begin transmitting within hours of tick attachment. CAPC’s 2025 Pet Parasite Forecast similarly warned that Lyme disease, ehrlichiosis, anaplasmosis, and heartworm continue to spread in the U.S., reinforcing the idea that parasite prevention is no longer a seasonal conversation in many markets. (fearfree.com)
The core comparison comes from a 2024 Parasites & Vectors paper evaluating three monthly isoxazoline-containing products against induced Amblyomma americanum infestations in dogs. In the study, 32 dogs were infested with 50 lone star ticks and then assigned to lotilaner, afoxolaner, sarolaner combination treatment, or untreated control groups. The published results showed that at 24 hours after treatment on day 0, both lotilaner and afoxolaner were faster than sarolaner, but over the monthly dosing interval lotilaner maintained higher residual speed of kill. By day 21 at 24 hours post-infestation, lotilaner efficacy was 97.4%, compared with 13.6% for sarolaner and 14.9% for afoxolaner, and the paper concluded that speed of kill declined significantly for sarolaner and afoxolaner, but not for lotilaner. Fear Free’s summary distilled that into a simpler clinical message: only the lotilaner-treated group reached at least 90% efficacy at every 24-hour evaluation. (parasitesandvectors.biomedcentral.com)
That matters because the lone star tick is both expanding and difficult to kill relative to some other common canine tick species. The study authors and subsequent Elanco materials describe Amblyomma americanum as less sensitive to isoxazolines than several other tick species, making it a useful stress test for comparative performance. Elanco later extended the commercial narrative by tying lotilaner to label expansions announced in 2025, including protection claims related to Lyme disease and efficacy data against the invasive longhorned tick. (parasitesandvectors.biomedcentral.com)
Industry and expert reaction has been predictably favorable from the manufacturer side. In Elanco’s August 15, 2024, release on the study, Auburn parasitologist Dr. Kathryn Reif said the findings matter because longer tick attachment increases pathogen transmission risk, and Elanco’s technical and marketing teams positioned the data as evidence that Credelio maintains rapid kill through the full month. Those comments align with the study’s direction, but they also come through a company press release tied to a branded product, so they should be read in that context. (elanco.com)
The second development in this story points to a broader market shift. TiCK MiTT is not a drug and doesn’t replace labeled acaricidal prevention, but its rollout into 900-plus Petco locations suggests growing retail demand for visible, hands-on tick management tools. The company says the mitt is designed to remove loose ticks from clothing, fur, or skin before they embed, and it is explicitly marketing the product around rising concern over year-round tick exposure. For clinics, that’s a reminder that pet parents are increasingly assembling their own prevention “stack,” combining prescriptions, physical checks, grooming habits, and over-the-counter tools. (petage.com)
Why it matters: For veterinary teams, this is really a story about communication and compliance. Speed of kill can be highly relevant in endemic areas, especially where lone star ticks or other high-risk vectors are common, but it’s only one factor in product choice alongside spectrum, duration, safety profile, patient history, household dynamics, and adherence. Isoxazolines remain important tools, yet their class labeling includes warnings about neurologic adverse reactions, including tremors, ataxia, and seizures, so individual patient risk still matters. The bigger opportunity may be helping pet parents understand layered prevention: year-round prescription protection where appropriate, routine tick checks, prompt removal, and realistic expectations about what adjunct retail products can and can’t do. (elanco.com)
What to watch: Watch for more comparative tick data, especially around longhorned tick spread and pathogen-specific transmission windows, and for more retail-clinic overlap as consumer brands market non-chemical tick tools alongside veterinary preventives during the 2026 tick season. (investor.elanco.com)